276 related articles for article (PubMed ID: 16301022)
41. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring.
Wiener GJ; Richter JE; Copper JB; Wu WC; Castell DO
Am J Gastroenterol; 1988 Apr; 83(4):358-61. PubMed ID: 3348191
[TBL] [Abstract][Full Text] [Related]
42. Interference with daily activities and major adverse events during esophageal pH monitoring with bravo wireless capsule versus conventional intranasal catheter: a systematic review of randomized controlled trials.
Iluyomade A; Olowoyeye A; Fadahunsi O; Thomas L; Libend CN; Ragunathan K; Fenster J; Vignesh S
Dis Esophagus; 2017 Feb; 30(3):1-9. PubMed ID: 26952638
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the different characteristics of sensed reflux events among different heartburn groups.
Schey R; Shapiro M; Navarro-Rodriguez T; Fass SS; Han B; Wendel C; Fass R
J Clin Gastroenterol; 2009 Sep; 43(8):699-704. PubMed ID: 18797407
[TBL] [Abstract][Full Text] [Related]
44. Wireless capsule pH monitoring: does it fulfil all expectations?
Maerten P; Ortner M; Michetti P; Dorta G
Digestion; 2007; 76(3-4):235-40. PubMed ID: 18174686
[TBL] [Abstract][Full Text] [Related]
45. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients.
Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):499-506. PubMed ID: 17489061
[TBL] [Abstract][Full Text] [Related]
46. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis.
Wu JC; Cheung CM; Wong VW; Sung JJ
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):690-5. PubMed ID: 17481961
[TBL] [Abstract][Full Text] [Related]
47. Improving the analysis of esophageal acid exposure by a new parameter: area under H+.
Rebecchi F; Di FI; Giaccone C; Morino M
Am J Gastroenterol; 2002 Mar; 97(3):568-74. PubMed ID: 11922548
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of endoscopic findings of erosive esophagitis in children: a population-based study.
Gilger MA; El-Serag HB; Gold BD; Dietrich CL; Tsou V; McDuffie A; Shub MD
J Pediatr Gastroenterol Nutr; 2008 Aug; 47(2):141-6. PubMed ID: 18664864
[TBL] [Abstract][Full Text] [Related]
49. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease.
Schey R; Dickman R; Parthasarathy S; Quan SF; Wendel C; Merchant J; Powers J; Han B; van Handel D; Fass R
Gastroenterology; 2007 Dec; 133(6):1787-95. PubMed ID: 18054551
[TBL] [Abstract][Full Text] [Related]
50. Impact of prolonged 48-h wireless capsule esophageal pH monitoring on diagnosis of gastroesophageal reflux disease and evaluation of the relationship between symptoms and reflux episodes.
Domingues GR; Moraes-Filho JP; Domingues AG
Arq Gastroenterol; 2011; 48(1):24-9. PubMed ID: 21537538
[TBL] [Abstract][Full Text] [Related]
51. Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry.
Ghoshal UC; Chourasia D; Tripathi S; Misra A; Singh K
Scand J Gastroenterol; 2008; 43(6):654-61. PubMed ID: 18569981
[TBL] [Abstract][Full Text] [Related]
52. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease.
Thoua NM; Khoo D; Kalantzis C; Emmanuel AV
Aliment Pharmacol Ther; 2008 Mar; 27(5):396-403. PubMed ID: 18081729
[TBL] [Abstract][Full Text] [Related]
53. Ambulatory esophageal pH monitoring by using a wireless system: a pilot study in Taiwan.
Tu CH; Lee YC; Wang HP; Wu MS; Chiu HM; Lin JT
Hepatogastroenterology; 2004; 51(60):1586-9. PubMed ID: 15532783
[TBL] [Abstract][Full Text] [Related]
54. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups.
Dickman R; Parthasarathy S; Malagon IB; Jones P; Han B; Powers J; Fass R
Aliment Pharmacol Ther; 2007 Jul; 26(1):41-8. PubMed ID: 17555420
[TBL] [Abstract][Full Text] [Related]
55. Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients.
Grigolon A; Cantù P; Savojardo D; Conte D; Penagini R
J Clin Gastroenterol; 2008 Oct; 42(9):969-73. PubMed ID: 18719508
[TBL] [Abstract][Full Text] [Related]
56. 24-h multichannel intraluminal impedance-pH monitoring may be an inadequate test for detecting gastroesophageal reflux in patients with mixed typical and atypical symptoms.
Han MS; Lada MJ; Nieman DR; Tschoner A; Peyre CG; Jones CE; Watson TJ; Peters JH
Surg Endosc; 2015 Jul; 29(7):1700-8. PubMed ID: 25398192
[TBL] [Abstract][Full Text] [Related]
57. Relevance of ineffective esophageal motility and hyperactive acid sensitization in patients with gastroesophageal reflux.
Hong SJ; Ko BM; Jung IS; Ryu CB; Moon JH; Cho JY; Kim JO; Lee JS; Lee MS; Shim CS; Kim BS
J Gastroenterol Hepatol; 2007 Oct; 22(10):1662-5. PubMed ID: 17559356
[TBL] [Abstract][Full Text] [Related]
58. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
Lee KJ; Kwon HC; Cheong JY; Cho SW
Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
[TBL] [Abstract][Full Text] [Related]
59. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial.
Wenner J; Johnsson F; Johansson J; Oberg S
Am J Gastroenterol; 2007 Feb; 102(2):239-45. PubMed ID: 17100971
[TBL] [Abstract][Full Text] [Related]
60. Bravo capsule for wireless 48-h pH monitoring: proposed algorithm for its placement.
Marchese M; Spada C; Costamagna G
Am J Gastroenterol; 2007 Sep; 102(9):2104-5; author reply 2106. PubMed ID: 17727439
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
